First evaluation of a human DPP4 transgenic hamster model for MERS-CoV pathogenesis and transmission
Schön, J.; Liu, Y.; Halwe, N. J.; Britzke, T.; Codjia Risch, M.-C. B.; Li, R.; Merrill, N.; Ulrich, L.; Rodon, J.; Bork, J.; Bösel, D.; Beyer, A.; Müller, M. A.; Drosten, C.; Breithaupt, A.; Hoffmann, D.; Wang, Z.; Beer, M.
Show abstract
MERS-CoV poses a constant pandemic risk, as its viral lineages continue evolving, and zoonotic spillover events could lead to random viral polymorphisms that might lead to human adapted variants. Currently, no small animal model reliably recapitulates both disease progression and transmission dynamics, which are critical aspects for counter-viral measures like vaccine development. Although the Syrian hamster is an optimal animal model for SARS-CoV-2 infection and transmission, it is naturally resistant to MERS-CoV infection. Dipeptidyl peptidase-4 (DPP4) is the functional receptor for MERS-CoV infection, and is highly expressed in human kidney, intestine, liver, and lung tissues. Here, we evaluated the suitability of a human DPP4 (hDPP4) transgenic Syrian hamster model for MERS-CoV research. We used two different MERS-CoV strains (EMC/2012 and D10540/2023) for intranasal inoculation of hamsters. Both strains replicated efficiently, led to comparable severe clinical outcomes, and had similar viral transmission efficiencies. MERS-CoV RNA and nucleoprotein antigen were mainly detected in the brain and the respiratory tract. In summary, we validated a novel hDPP4-transgenic hamster as a suitable model for MERS-CoV infection enabling vaccine and transmission research.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.